Knights of Columbus Asset Advisors LLC Decreases Holdings in Boston Scientific Corporation $BSX

Knights of Columbus Asset Advisors LLC lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 65.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,158 shares of the medical equipment provider’s stock after selling 44,543 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Boston Scientific were worth $2,208,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Egerton Capital UK LLP boosted its holdings in Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after buying an additional 3,671,548 shares during the last quarter. Alphinity Investment Management Pty Ltd purchased a new position in shares of Boston Scientific in the fourth quarter valued at approximately $252,918,000. Marshall Wace LLP lifted its position in shares of Boston Scientific by 30.7% in the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after acquiring an additional 2,301,383 shares in the last quarter. Credit Agricole S A acquired a new stake in shares of Boston Scientific in the third quarter worth approximately $204,812,000. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Boston Scientific by 28.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 8,367,398 shares of the medical equipment provider’s stock worth $816,909,000 after purchasing an additional 1,837,480 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BSX shares. Evercore decreased their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Argus raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. Bank of America cut their price target on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a report on Monday, May 18th. Finally, National Bank Financial set a $115.00 target price on Boston Scientific in a research note on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.46.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This represents a 16.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 9,800 shares of company stock worth $554,012 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $49.12 on Friday. The firm has a 50-day simple moving average of $60.69 and a two-hundred day simple moving average of $78.84. The stock has a market cap of $73.01 billion, a PE ratio of 20.55, a P/E/G ratio of 0.93 and a beta of 0.62. Boston Scientific Corporation has a 1-year low of $48.41 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter last year, the company posted $0.75 EPS. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 3.37 EPS for the current year.

Boston Scientific declared that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.